Related Experiment Video
Updated: Jul 16, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Bupropion: new therapy for depression
1Hahnemann University School of Medicine, Philadelphia, Pennsylvania.
Abstract:
Bupropion is one of the most recently approved antidepressant drugs. The drug differs in chemical structure from the tricyclic antidepressants. It mechanism of action is unknown. Bupropion weakly blocks dopamine uptake, but this property does not seem to account for the antidepressant effects. In clinical trials, bupropion has shown satisfactory antidepressant action compared with placebo. Because long-term effects are not well established, bupropion should be discontinued after several months of therapy.
More Related Videos
05:19Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder
Published on: July 7, 2023
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Related Concept Videos
G-protein Coupled Receptors
Depression: Overview
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Drug Therapy
Antianxiety Medications